Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.16357
Abstract: Key Points Question What are the incremental lifetime and phase-specific Medicare costs for older adults with multiple myeloma? Findings In this cohort study of data from 4533 patients with multiple myeloma, the incremental lifetime multiple… read more here.
Keywords: cost; multiple myeloma; lifetime; phase specific ... See more keywords
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.28877
Abstract: Key Points Question Is there equitable geographic access to chimeric antigen receptor–T cells (CAR-T) and bispecific antibodies trials for multiple myeloma in the US? Findings In this cross-sectional study of data from 69 clinical trials… read more here.
Keywords: trials multiple; multiple myeloma; antibodies trials; access chimeric ... See more keywords
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.3971
Abstract: Importance High-risk smoldering myeloma has a 5-year risk of progression to symptomatic multiple myeloma of approximately 75%. Treatment with lenalidomide decreases the risk of progression; however, novel triplet regimens are superior, and earlier disease may… read more here.
Keywords: risk; smoldering myeloma; high risk; multiple myeloma ... See more keywords
Chemotherapy-Induced Hyperopic Surprise in a Woman With Multiple Myeloma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2022.3226
Abstract: This case report describes a woman aged 64 years with a history of multiple myeloma who presented with worsening vision after receiving an infusion of belantamab mafodotin. read more here.
Keywords: hyperopic surprise; chemotherapy induced; induced hyperopic; multiple myeloma ... See more keywords
Acute-Onset Orbital Inflammation in a Patient With Multiple Myeloma.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2023.0021
Abstract: A 72-year-old man presented with right eye conjunctival injection, chemosis, eyelid edema, and pain with eye movements. Examination of the right eye was notable for visual acuity of 20/50, reduced ocular motility in all gazes,… read more here.
Keywords: onset orbital; orbital inflammation; inflammation patient; patient multiple ... See more keywords
Microfluidic enrichment of plasma cells improves treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12201
Abstract: Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false‐negatives due to the unpredictable distribution… read more here.
Keywords: cytogenetic alterations; multiple myeloma; plasma cells; cd45 ... See more keywords
Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Oncology"
DOI: 10.1002/1878-0261.70085
Abstract: Cyclins D could be a unifying event in multiple myeloma (MM), even though MM is not typically considered a proliferative disease. In this study, we hypothesized that cyclins D might have additional roles in the… read more here.
Keywords: multiple myeloma; cell cycle; cyclin pathogenesis; cell ... See more keywords
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.
Sign Up to like & getrecommendations! Published in 2025 at "Molecular oncology"
DOI: 10.1002/1878-0261.70120
Abstract: Despite significant advancements, multiple myeloma (MM) remains incurable, largely due to drug resistance. Our previous research has demonstrated that proline metabolism plays a role in MM progression and that inhibiting PYCR1, the final enzyme in… read more here.
Keywords: multiple myeloma; enhances bortezomib; metabolism; bone marrow ... See more keywords
PINK1‐Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B‐Mediated Hippo‐YAP/TAZ Pathway
Sign Up to like & getrecommendations! Published in 2020 at "Advanced Science"
DOI: 10.1002/advs.201900860
Abstract: Abstract The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN‐induced putative kinase 1 (PINK1)‐dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels of the PINK1‐dependent mitophagy… read more here.
Keywords: multiple myeloma; pink1 dependent; dependent mitophagy; myeloma ... See more keywords
Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Science"
DOI: 10.1002/advs.202104491
Abstract: Abstract It has been previously shown that (never in mitosis gene A)‐related kinase 2 (NEK2) is upregulated in multiple myeloma (MM) and contributes to drug resistance. However, the mechanisms behind this upregulation remain poorly understood.… read more here.
Keywords: aberrations interaction; interaction nek2; multiple myeloma; nek2 tp53 ... See more keywords
Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced science"
DOI: 10.1002/advs.202301377
Abstract: Multiple myeloma (MM) is a cancer of differentiated plasma cells that occurs in the bone marrow (BM). Despite the recent advancements in drug development, most patients with MM eventually relapse and the disease remains incurable.… read more here.
Keywords: lipid nanoparticles; bone marrow; cd38; rna ... See more keywords